Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Status:
Recruiting
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo-controlled, randomized phase 3 study with phase
1b portion designed to establish a recommended phase 3 dose (RP3D) and to evaluate the
efficacy, PK, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects
with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.